Search results for "Type 1 Diabete"

showing 10 items of 208 documents

Real-time estimation of plasma insulin concentration from continuous glucose monitor measurements

2015

Continuous glucose monitors can measure interstitial glucose concentration in real time for closed-loop glucose control systems, known as artificial pancreas. These control systems use an insulin feedback to maintain plasma glucose concentration within a narrow and safe range, and thus to avoid health complications. As it is not possible to measure plasma insulin concentration in real time, insulin models have been used in literature to estimate them. Nevertheless, the significant interand intra-patient variability of insulin absorption jeopardizes the accuracy of these estimations. In order to reduce these limitations, our objective is to perform a real-time estimation of plasma insulin co…

Blood GlucoseMaleInsulin pump0209 industrial biotechnologymedicine.medical_treatmentBiomedical EngineeringArtificial pancreas030209 endocrinology & metabolismBioengineering02 engineering and technologyArtificial pancreas03 medical and health sciencesExtended Kalman filter020901 industrial engineering & automation0302 clinical medicineComputer SystemsTime estimationmedicineHumansInsulinComputer SimulationObservabilityMathematicsType 1 diabetesBlood Glucose Self-MonitoringInsulinReproducibility of ResultsGlucose insulin modelsGeneral MedicineMiddle AgedModels Theoreticalmedicine.diseaseINGENIERIA DE SISTEMAS Y AUTOMATICAExtended Kalman filterComputer Science ApplicationsHuman-Computer InteractionDiabetes Mellitus Type 1Type 1 diabetesFemalePlasma insulinMATEMATICA APLICADAAlgorithmsInsulin estimationBiomedical engineeringComputer Methods in Biomechanics and Biomedical Engineering
researchProduct

Extensive Assessment of Blood Glucose Monitoring During Postprandial Period and Its Impact on Closed-Loop Performance.

2017

[EN] Background: Closed-loop (CL) systems aims to outperform usual treatments in blood glucose control and continuous glucose monitors (CGM) are a key component in such systems. Meals represents one of the main disturbances in blood glucose control, and postprandial period (PP) is a challenging situation for both CL system and CGM accuracy. Methods: We performed an extensive analysis of sensor¿s performance by numerical accuracy and precision during PP, as well as its influence in blood glucose control under CL therapy. Results: During PP the mean absolute relative difference (MARD) for both sensors presented lower accuracy in the hypoglycemic range (19.4 ± 12.8%) than in other ranges (12.2…

Blood GlucoseMaleTime FactorsGlucose controlEndocrinology Diabetes and MetabolismSpecial Section: Artificial Pancreas: Models Signals and Control0302 clinical medicineInsulin030212 general & internal medicineContinuous glucose monitoringAccuracymedicine.diagnostic_testContinuous glucose monitoringPostprandial periodSignal Processing Computer-AssistedMiddle AgedPostprandial PeriodINGENIERIA DE SISTEMAS Y AUTOMATICAType 1 diabetesPostprandialTreatment OutcomeClosed-loop controlCardiologyFemaleGlucose monitorsAlgorithmsAdultmedicine.medical_specialtyTransducersBiomedical Engineering030209 endocrinology & metabolismBioengineering03 medical and health sciencesInsulin Infusion SystemsPredictive Value of TestsInternal medicineInternal MedicinemedicineHumansHypoglycemic AgentsBlood glucose monitoringType 1 diabetesbusiness.industryBlood Glucose Self-MonitoringReproducibility of Resultsmedicine.diseaseHypoglycemiaEndocrinologyDiabetes Mellitus Type 1businessClosed loopBiomarkersJournal of diabetes science and technology
researchProduct

Bone status in adolescents with type 1 diabetes

2010

Aims The aim of the study was to investigate the potential negative impact of type 1 diabetes on bone status of adolescents. Bone status in adolescents with type 1 diabetes was assessed by means of quantitative ultrasound (QUS) and the influence of metabolic control and other diseaserelated and growth variables was analysed. Methods Group I consisted of 99 pubertal (Tanner ≥2) adolescents (49 female), aged 14.3±2.5 years, diabetes duration 4.6±2.3 years. Controls (group II) were 297 children, matched by sex and age, from a healthy population. The influence of glycated haemoglobin (current: HbA1cD; last year’s mean: HbA1cY; whole duration mean: HbA1cT), diabetes duration, percentage of life …

Blood GlucoseMalemedicine.medical_specialtyHbA1cAdolescentEndocrinology Diabetes and Metabolismmedicine.medical_treatmentDiseaseBone and BonesStatistics NonparametricSurveys and QuestionnairesDiabetes mellitusInternal medicineImmunopathologyInternal MedicineHumansMedicineChildChromatography High Pressure LiquidUltrasonographyGlycated HemoglobinAnalysis of VarianceType 1 diabetesbusiness.industryPatient SelectionInsulinPubertymedicine.diseaseAdolescenceQuantitative ultrasoundDiabetes Mellitus Type 1EndocrinologyType 1 diabetesMetabolic control analysisFemaleAnalysis of variancebusinessQuantitative ultrasoundDiabetologia
researchProduct

The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model b…

2014

Objective In diabetes, vascular dysfunction is characterized by impaired endothelial function due to increased oxidative stress. Empagliflozin, as a selective sodium-glucose co-transporter 2 inhibitor (SGLT2i), offers a novel approach for the treatment of type 2 diabetes by enhancing urinary glucose excretion. The aim of the present study was to test whether treatment with empagliflozin improves endothelial dysfunction in type I diabetic rats via reduction of glucotoxicity and associated vascular oxidative stress. Methods Type I diabetes in Wistar rats was induced by an intravenous injection of streptozotocin (60 mg/kg). One week after injection empagliflozin (10 and 30 mg/kg/d) was adminis…

Blood GlucoseMalemedicine.medical_treatmentReceptor for Advanced Glycation End Productslcsh:MedicineGene ExpressionType 2 diabetesmedicine.disease_causeVascular MedicineGlucosidesMedicine and Health SciencesMedicineInsulinEndothelial dysfunctionReceptors Immunologiclcsh:ScienceMultidisciplinaryType 1 DiabetesCytokinesInflammation Mediatorsmedicine.drugSignal TransductionResearch Articlemedicine.medical_specialtyCardiologyBlood sugarStreptozocinCardiovascular PharmacologyDiabetes Mellitus ExperimentalDiabetes ComplicationsInternal medicineDiabetes mellitusEmpagliflozinDiabetes MellitusAnimalsRNA MessengerVascular DiseasesBenzhydryl CompoundsSodium-Glucose Transporter 2 InhibitorsPharmacologybusiness.industryInsulinlcsh:RHemodynamicsStreptozotocinmedicine.diseaseRatsOxidative StressEndocrinologyGlucoseMetabolic Disorderslcsh:QbusinessOxidative stressDiabetic AngiopathiesPloS one
researchProduct

Advances in pharmacological treatment of type 1 diabetes during pregnancy.

2019

Introduction: In women with type 1 diabetes mellitus (T1DM), pregnancy is associated with a potential risk of maternal, foetal and neonatal outcomes. Stringent metabolic control is required to improve these outcomes. Areas covered: In this review, the authors summarise the current evidence from studies on the pharmacological therapy and on monitoring of T1DM during pregnancy. The authors also discuss the use of new technologies to improve therapeutic management and patient compliance. Expert opinion: Pre-conception counselling is essential in T1DM to minimise pregnancy risks. Pregnancy in T1DM is always considered a high-risk pregnancy. During pregnancy, the target haemoglobin A1C (HbA1c) i…

Blood Glucoseendocrine system diseasesPregnancy in DiabeticsDiabetic complicationBioinformaticsPharmacological treatmenttype 1 diabetes mellitu03 medical and health sciences0302 clinical medicinePregnancymedicineHumansHypoglycemic AgentsInsulinPharmacology (medical)PharmacologyType 1 diabetesPregnancyPotential riskbusiness.industryCesarean Sectionnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseHypoglycemiaglycaemic controlDiabetes Mellitus Type 1Neonatal outcomes030220 oncology & carcinogenesisMetabolic control analysisFemalebusiness030217 neurology & neurosurgeryExpert opinion on pharmacotherapy
researchProduct

Clinical Approach to Flash Glucose Monitoring: An Expert Recommendation

2019

The flash glucose monitoring (FGM) system FreeStyle Libre® is a device that measures interstitial glucose in a very simple way and indicates direction and speed of glucose change. This allows persons with diabetes to prevent hypoglycemic and hyperglycemic events. Scientific evidence indicates that the system can improve glycemic control and quality of life. To obtain the maximum benefit, it is necessary to properly handle glucose values and trends. Due to the generalization of the system use, the purpose of the document is to provide recommendations for the optimal use of the device, not only in the management of glucose values and trends but also in the prevention of hypoglycemia, actuati…

Blood Glucosemedicine.medical_specialtyComputer scienceEndocrinology Diabetes and MetabolismBiomedical EngineeringBioengineeringType 2 diabetesHypoglycemiaFlash (photography)Quality of life (healthcare)CommentariesDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic AgentsInsulinIntensive care medicineRetrospective StudiesGlycemicType 1 diabetesBlood Glucose Self-Monitoringmedicine.diseaseHypoglycemiaDiabetes Mellitus Type 1Quality of LifeInterstitial glucoseJournal of Diabetes Science and Technology
researchProduct

Glycemic Variability Assessment with a 14-Day Continuous Glucose Monitoring System: When and How Long to Measure MAGE (Mean Amplitude of Glucose Excu…

2021

Mean amplitude of glucose excursion (MAGE) is considered as the “gold standard” for assessing the short-term within-day glycemic variability (GV), which is an important component of overall glycemic control. A 14-day continuous glucose monitoring system is now widely used and allows easier assessment of GV. However, it is still unknown whether MAGE, usually calculated on a 48-hour period is identical whatever the time during the 14-day lifespan of the sensor and whether a longer time period might give additional information. We evaluated in 68 patients with type 1 diabetes, MAGE during three 2-day periods (day1-day3; day6-day8; day11-day13) and during periods of 3 days and 4 days. MAGE cal…

Blood Glucosemedicine.medical_specialtyEndocrinology Diabetes and MetabolismBiomedical Engineering030209 endocrinology & metabolismBioengineering030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineTechnology ReportsInternal MedicinemedicineHumansReliability (statistics)GlycemicType 1 diabetesContinuous glucose monitoringbusiness.industryBlood Glucose Self-MonitoringReproducibility of ResultsGold standard (test)Glucose excursionmedicine.diseaseGlucoseAmplitudeDiabetes Mellitus Type 2CardiologybusinessJournal of Diabetes Science and Technology
researchProduct

Biosimilars and Novel Insulins.

2019

Background Insulin therapy is the mainstay of treatment for type 1 diabetes and may be necessary in type 2 diabetes. Current insulin analogues present a more physiological profile, are effective, and with less risk of hypoglycemia, but they are expensive. Biosimilar insulins should offer the advantages of insulin analogues at reduced costs. In addition, current rapid-acting insulin analogues are not fast enough to control excessive postprandial glucose excursions in many patients. Areas of uncertainty Biosimilar insulins demonstrated that are safe and effective, but interchangeability and automatic substitution remain an issue. Ultrafast-acting insulins should reduce postprandial hyperglyce…

Blood Glucosemedicine.medical_specialtyendocrine system diseasesmedicine.medical_treatmentInsulin GlargineType 2 diabetes030204 cardiovascular system & hematologyHypoglycemiaInsulin aspart03 medical and health sciences0302 clinical medicinemedicineInsulin lisproHumansHypoglycemic AgentsPharmacology (medical)030212 general & internal medicineIntensive care medicineBiosimilar PharmaceuticalsRandomized Controlled Trials as TopicPharmacologyGlycated HemoglobinType 1 diabetesInsulin Lisprobusiness.industryInsulin glargineInsulinnutritional and metabolic diseasesBiosimilarGeneral Medicinemedicine.diseaseDiabetes Mellitus Type 1Diabetes Mellitus Type 2Hyperglycemiabusinessmedicine.drugAmerican journal of therapeutics
researchProduct

Ambulatory Glucose Profile Applied to Flash Glucose Monitoring in Real Life: An Expert Opinion.

2016

The clinical benefits of real time continuous glucose monitoring (rtCGM) use have been well demonstrated in both CSII- and MDI-treated individuals in large clinical trials. However, recommendations for patient use of rtCGM in everyday life situations are lacking. This article provides guidance to clinicians and patients with type 1 diabetes (T1D) in effective use of rtCGM data, including glucose rate of change (ROC) arrows, for insulin dosing adjustments and other treatment decisions. The recommendations presented here are based on our own clinical experiences as endocrinologists, our personal experiences living with T1D using rtCGM, and findings from a recent survey of T1D patients who hav…

Blood Glucosemedicine.medical_specialtymultiple daily insulin injectionstype 1 diabetesEndocrinology Diabetes and MetabolismMonitoring ambulatoryBiomedical Engineeringflash glucose monitoringrate of changeMonitoring Ambulatory030209 endocrinology & metabolismBioengineeringglucose-monitoring systemMDI03 medical and health sciencesFlash (photography)0302 clinical medicineDiabetes mellitusBlood Glucose Self-MonitoringmedicineInternal MedicineIn real lifeambulatory glucose profile; diabetes; flash glucose monitoring; glucose-monitoring systems; glycemic control030212 general & internal medicineglucose-monitoring systemsIntensive care medicineambulatory glucose profileExpert TestimonyReview Articlesdiabetesbusiness.industryMedicine (all)Blood Glucose Self-MonitoringCSIImedicine.diseaseDiabetes Mellitus Type 1GlucosediabeteExpert opinioninsulin pumpAmbulatoryglucose profileglycemic controlcontinuous glucose monitoringMedical emergencybusinessJournal of diabetes science and technology
researchProduct

Agent +014 health program: gamification applied to the education of adolescents with diabetes according to the Precede-Proceed model and from a salut…

2021

Resumen Objetivos: la diabetes mellitus tipo 1 es una enfermedad crónica que suele debutar en la infancia y necesitar formación a lo largo para dar respuesta a los cambios producidos en todas las etapas vitales. El objetivo de esta investigación es desarrollar un programa de educación para la salud, siguiendo el modelo Precede-Procede y desde una perspectiva salutogénica atendiendo a las necesidades de la población adolescente y que incluya la gamificación como estrategia educativa. Materiales y métodos: la primera fase es investigación mixta, cuantitativa y cualitativa y combina diferentes instrumentos para la recogida de información. Los participantes son adolescentes con dicho diagnóstic…

Community and Home CareHealth (social science)juegoHealth Policydiabetes mellitus tipo 1EspañaPublic Health Environmental and Occupational HealthEspanhaHealth Professions (miscellaneous)Health educationdisease managementEducação em saúdeSpainmanejo da doençajogoEducación en saludmanejo de la enfermedadplaytype 1 diabetes mellitus
researchProduct